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We have reinvestigated a classification of 
clinical heterogeneity among cystic fibrosis 
(CF) patients that we previously reported and 
investigated the possible relationship of the 
identified CF subgroups to haplotypes 
around the CF gene and to HLA-DR haplo- 
types. Age-corrected values for sweat electro- 
lytes, rate of progression of lung disease as 
assessed by Brasfield chest x-ray scores, and 
severity of pancreatic insufficiency as as- 
sessed by daily supplemented enzyme dosage 
were obtained for 55, 59, and 59 patients, re- 
spectively. XV-2c and KM19 RFLPs were de- 
termined by hybridization to TaqI and PstI 
digests of human genomic DNA, respectively, 
and analysis of mutations by PCR amplifica- 
tion followed by allele-specific oligo-deoxy- 
nucleotide hybridization was performed for 
29 patients. HLA-DR restriction fragment 
length polymorphisms (RFLPs) were deter- 
mined by hybridization of cDNA p l  and ge- 
nomic DQol probes to TaqI digests of human 
genomic DNA. The results show that the pre- 
vious subdivision on the basis of age-cor- 
rected levels of sweat electrolytes, as well as 
measures of severity of lung disease and pan- 
creatic disease, is valid. In addition, the C and 
D haplotypes are associated with lower age- 
corrected sweat sodium level. No significant 
relationship between C F  haplotypes and the 
other two disease variables or between HLA- 
DR haplotypes and any of the clinical vari- 
ables was found. 
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INTRODUCTION 
Cystic fibrosis (CF) is the most common autosomal 
recessive disorder in Caucasians, affecting about one in 
2,500 live births, with a carrier frequency of one in 25. 
The basic defect in CF is probably a genetic alteration in 
the control of chloride transport [Quinton and Bigman, 
1983; Welsh and Liedtke, 19881. The CF gene was at  
first mapped to chromosome 7 band q21-31 by linkage 
to multiple DNA markers [Knowlton et al., 1985; Scam- 
bler et al., 1988; Tsui et a]., 1985; Wainwright et al., 
1985; White et al., 19851 and recently has been cloned 
and partially characterized [Rommens et al., 1989; Rior- 
dan et al., 1989; Kerem et al., 1989~1, with results sug- 
gesting that there is a probable defect in chloride trans- 
port. The presenting clinical symptoms of the disease 
are related mainly to chronic obstructive pulmonary 
involvement and malfunction of exocrine glands, lead- 
ing to pancreatic enzyme insufficiency and elevation of 
sodium and chloride ions in sweat [Wood et al., 19761. 
The considerable heterogeneity of clinical manifesta- 
tions of CF is well documented. This phenomenon might 
reflect genetic heterogeneity of the disorder; e.g., differ- 
ences among patients for features such as pancreatic 
function [Kerem et al., 1989al and meconium ileus 
[Kerem et al., 198913; Mornet et al., 1988, 19891 seem to 
be genetically determined. Also the distribution of hap- 
lotypes recognized by various molecular probes varies in 
different populations studied [Cutting et al., 1989; De- 
voto et al., 1989; Estivill et al., 1987a; Stern et al., 19761, 
which also suggests genetic heterogeneity. 
In a previous study from this laboratory, different 
combinations of primary clinical variables were used for 
subgrouping individuals affected with CF [Sing et al., 
19821. Four distinct subgroups (clusters) of individuals 
who varied in their laboratory values and clinical course 
of the disease were identified. This heterogeneity was 
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based on three age corrected variables: sweat sodium 
level, pancreatic enzyme dosage, and severity of lung 
disease as judged by chest x-ray scores. It was shown 
that the information contributed by the sweat level to 
the clinical heterogeneity of CF patients separated clus- 
ters 1 and 2 from clusters 3 and 4 and was independent of 
the relationship between pancreatic damage and pulmo- 
nary function (which separated clusters 1 and 3 from 
clusters 2 and 4). 
In the present study, the same set of clinical variables 
was used on a set of new patients to reappraise the 
original separation criteria and to search for correla- 
tions of clinical status of CF patients with four haplo- 
types recognized by probes XV-2c and KM19, which 
show significant linkage disequilibrium with the CF 
mutation IEstivill et al., 1987a, 1987bl. Because of the 
high incidence of diabetes (which has known HLA asso- 
ciations) in patients with CF [Knowles and Fernald, 
1988; Rodman et al., 19861, variable reports of a nonran- 
dom distribution of HLA-specificities in CF patients 
[Kaiser et al., 1977; Hennequet et al., 1978; Herrod et 
al., 1979; Polymenidis et al., 19731, and the suggestion of 
a role of autoimmunity in this disorder [Geffner et al., 
1988; Wilkin et al., 19871, we also screened part of our 
study group for HLA-Dr haplotypes [Cox et al., 19881. 
MATERIALS AND METHODS 
A sample of 59 individuals of Caucasian origin af- 
fected with CF was studied. Forty-two were patients a t  
the Mott Children’s Hospital of the University of Michi- 
gan in Ann Arbor; 17 were from Wyler Children’s Hospi- 
tal, The University of Chicago, and Children’s Memorial 
Hospital, Northwestern University of Chicago. Clinical 
data were collected by physicians in CF clinics. Sweat 
sodium levels were available for 55 individuals. Only 
levels higher than 70 mEq/L were considered to support 
a CF diagnosis. Pulmonary involvement was measured 
by chest x-ray severity score using the Brasfield scoring 
system. However, pulmonary damage was classified as 
one of four discrete classes ranging from 1 (the least 
severe, Brasfield score 19-25) to 4 (the most severe, 
Brasfield score 1-6). The Brasfield score was available 
for 59 individuals. GI tract involvement was quanti- 
tated in terms of the dosage of pancreatic enzyme sup- 
plementation. The standard enzyme dose was expressed 
in terms of equivalent number of Pancrease capsules per 
day. The relative medication strength based on lipase 
content was as follows: Pancrease 4, Cotazym and Co- 
tazym S 5, Creon 8, and Zymase 12. The equivalent 
Pancrease dose was arrived a t  by the equation: Pancre- 
ase dose = (medication strength x number of capsules a 
day) I 4. Enzyme dosage was available in 59 cases. 
The deviation of an individual’s age a t  exam from the 
average of all exam ages for those who share this grade 
of pulmonary involvement was taken as an age-cor- 
rected measure of pulmonary severity. Individuals with 
positive deviations, regardless of their severity rating 
for the pulmonary variable, are assumed to be experi- 
encing a less severe course of the disease than those who 
deviate negatively. Sweat sodium levels were adjusted 
by linear regression to average age of diagnosis. Pancre- 
atic enzyme dosage was also adjusted by linear regres- 
sion for age a t  current dose. Age-corrected measures of 
“severity” for all three variables were then used in all 
analyses, rather than contrasting the severity rating 
directly (since severity is so age dependent). To compare 
principal components of the old and new study, two ap- 
proaches were used. The first was the angular compari- 
son of eigenvectors of principal components from both 
studies. In the second approach, new principal compo- 
nent scores, based on the previous study, were created by 
including new data into functions L1, L2, and L3 of Sing 
et al. [19821. The bivariate scatter of L2 and L3 was 
plotted and cutpoints from the previous study were used 
to check the clustering within the new sample of CF 
individuals. 
For restriction fragment length polymorphisms 
(RFLP) analyses, human genomic DNA was isolated 
from a 5-30 ml sample of whole blood according to the 
method of Kunkel et al. [19771 with a slight modifica- 
tion. Routinely, 5 pg of DNA was digested with restric- 
tion enzyme according to manufacturer’s protocols, elec- 
trophoresed through 0.9% agarose in tris-borate buffer, 
and transferred to Hybond-N membrane (Amersham) in 
10 x SSC. The filters were hybridized in 1 M NaCl,l% 
SDS, 10% dextran sulphate, overnight a t  65°C. Molecu- 
lar probes were labeled by oligolabelling method [Fein- 
berg and Vogelstein, 19841. Filters were washed to final 
stringency of 1 x SSC a t  65°C and exposed to Kodak 
XAR film at - 70°C with intensifying screens (Dupont 
Cronex Lightening-Plus). Molecular probes XV-2c and 
KM19 [Estivill et al., 1987a, 1987b1, recognizing RFLPs 
within TuqI and PstI digests, respectively, were used. 
These probes, obtained from Dr. Robert Williamson, 
were used to determine haplotypes for family counsel- 
ing, and subsequently the data were used for this study. 
Haplotypes were named according to a published no- 
menclature [Beaudet et al., 19881. 
For HLA-DR typing on DNA, a cDNA p l  probe [Long 
et al., 19831 and a genomic DQa probe [Trowsdale et al., 
19831, obtained from Dr. Richard Spielman, were used. 
Filters with TuqI digests of CF families’ DNA samples 
served for the detection of band patterns specific for 18 
different DR antigen types and their combinations [Cox 
et al., 19883. Following hybridization, the filters were 
washed to a final stringency of 0.1 x SSC a t  65°C. In 
cases in which the pattern shared by antigens DR7 
andlor DRw9-which are indistinguishable with probes 
DRpl and DQa in Tug1 digests, were detected-the hap- 
lotypes were all arbitrarily classified as  DR7. This is 
justified by a very low frequency of DRw9 in Caucasians 
[Cox et al., 19881. Complete DR antigen type data were 
available for 33 CF patients. 
In order to detect the A F508 mutation, DNA was 
amplified using the polymerase chain reaction (PCR); 
1 pM each of primers C16B and C16D [Kerem et al, 
1989c, 1989d1, which flank the region containing the 
mutation, was used with 1 pg genomic DNA and 2.5 
units Tuq polymerase in a total volume of 100 p l .  An- 
nealing conditions were 45 seconds a t  62”C, extension 
was 2 minutes a t  72”C, and denaturation was 1 minute 
a t  94°C for a total of 30 cycles. Then 5 pl of amplified 
product were denatured in 0.4N NaOH, added to 0.2 x 
SSC, and dot-blotted to nylon membranes. 
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The A F508 mutation was detected using sequence 
specific oligonucleotides (SSOs) for the mutated 
(oligo-AF) and the normal sequence (Oligo-N) [Kerem et 
al., 1989~1. SSOs were end-labelled with gamma-(32P)- 
ATP and hybridized to filter-bound DNA for 12 hours a t  
42°C in 0.5M NaC1, 50 mM NaPO,, 1% SDS, 5X Den- 
hardts, and 200 kgiml salmon sperm DNA. Membranes 
were washed twice at room temperature for 30 minutes 
in 5 x SSC and 1% SDS and once at 65°C for 30 minutes 
each in 2 x SSC and 1% SDS. Hybridization was visu- 
alized by an autoradiograph. 
RESULTS 
In order to check the effect of particular XV-2clKM19 
haplotypes on the three clinical variables studied, the 
percent distribution of haplotypes A, B, C, D, and com- 
bined haplotypes A + B, A + C, B + D, C + D (not 
shown) in negative and positive deviation groups has 
been calculated for the group of 59 patients. An analysis 
of variance using average deviation in sweat sodium 
levels, average age deviation from x-ray age class, and 
average deviation in pancreatic enzyme dose was per- 
formed. The values for heterozygous individuals were 
assigned 5050 to  each allele. The results are shown in 
Tables 1-111. The difference in sweat sodium levels for a 
group of patients with combined haplotypes A + B vs. a 
group with combined haplotypes C + D is significant at 
P < .05 (Table I, analysis of variance). None of the 
differences in x-ray severity (Table 11) nor pancreatic 
sufficiency (Table 111) are statistically significant. 
After this analysis was completed, the CF gene was 
cloned and the AF508 mutation was found to be the most 
common mutation, explaining 75% of CF mutations 
[Kerems et  al., 1989~1. The AF508 mutation is most 
commonly associated with the B haplotype and the B 
haplotype preferentially carries this mutation (al- 
though not in Ashkenazi Jewish populations). In order 
to see whether or not the B haplotypes of our patients 
predominately carried the AF508 mutation, PCR ampli- 
fication and allele-specific oligodeoxynucleotide hybrid- 
ization was performed on the 29 patients for whom DNA 
samples were still available. As seen in Table IV, the 
majority of BB homozygotes were homozygous for 
AF508, and 76.8% of B haplotypes were associated with 
the AF508 mutation, whereas the AF508 mutation was 
associated with other haplotypes only 37.5% of the time 
in our patient population. (We have assumed that the 
AF508 mutation was associated with the B haplotype in 
B heterozygous, AF508 heterozygous individuals.) 
A subgroup of 33 individuals (all from the University 
of Michigan) was HLA-DR typed. An example of a 
Southern blot with several HLA-DR types patterns is 
TABLE I. Sweat SodiumiAge at Diagnosis 
Percent of haplotypes in  deviation group 
Deviation N A B C D Total 
Negative 62 8.06 70.97 6.45 14.52 52.54 
Positive 56 17.86 75.00 0.00 7.14 47.46 
6 G = 8.96 
Analysis of variance: haplotype effect 
A 14 2.37 3 0.0998 
B 80 1.02 
C 4 - 12.35 
D 12 - 5.44 
A + B  94 1.22 1 0.0150 
C + D  16 - 7.17 
A + C  18 - 0.90 1 0.5177 
B + D  92 0.18 
P = 0.030 
N Mean DF P 
TABLE 11. Age DeviationiX-rav Class 
Percent of haplotypes in  deviation group 
Deviation N A B C D Total 
Negative 70 11.43 77.14 4.29 7.14 59.32 
Positive 48 14.58 66.67 2.08 16.67 40.68 
G = 3.38 
P = 0.337 
N Mean DF P 
Analysis of variance: haplotype effects 
A 15 4.81 3 0.2912 
B 86 - 1.06 
C 4 - 0.21 
D 13 1.50 
A + B  101 -0.18 1 0.7291 
C + D  17 1.10 
A + C  19 3.75 1 0.5600 
B + D  99 - 0.72 
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TABLE 111. Enzyme Dose1Ag.e When First Given Medication 
Percent of haplotypes in deviation group 
Deviation N A B C D Total 
Positive 52 7.69 82.69 1.92 7.69 44.07 
Negative 66 16.67 65.15 4.55 13.64 55.93 
G = 4.75 
P = 0.191 
Analysis of variance: haplotype effects 
N Mean DF P 
A 15 - 1.81 3 0.2495 
B 86 1.10 
C 4 - 10.30 
D 13 - 2.05 
A + R  101 0.67 1 0.1401 ~~ 
c + D  17 - 3.99 
A + C  19 - 3.59 1 0.1576 
B + D  99 0.69 
1 2 TABLE IV. Distributions of the AF508 Mutation Among XV-2c and KM19 HadotvDes 3 4 5 6 
AF508 
Haplotype Homozygous Heterozygous Negative 
AA 1 
AB 2 3 
BB 12 3 
BC 1 
BD 3 3 1 
-~ 
shown in Figure 1. Eleven different HLA-DR haplotypes 
were recognized among these individuals, and the dis- 
tribution of all of them between clusters 1 + 2 and 3 + 4, 
constructed according to Sing et al. [1982], was evalu- 
ated (Table V). The distribution of HLA-DR types in the 
sample studied (66 haplotypes) is not different from a 
random distribution among the cluster subgroup. Table 
VI presents the same analysis as  in Table V, but the 
distribution of HLA-DRw6 (the only candidate for par- 
ticipation in heterogeneity as shown in Table V) was run 
against all other types pooled together. These differ- 
ences also are not statistically significant. 
We have compared principal components analyses of 
the group of individuals studied currently with the 
group of individuals described before by Sing et 
al.119821. The principal components obtained for a 
group of 42 individuals (from University of Michigan 
Medical Center only) were: L1 = - 0.68 (sweat) + 0.41 
(dose) + 0.61 (x-ray age) L2 = 0.10 (sweat) + 0.88 (dose) 
- 0.47 (x-ray age) L3 = 0.73 (sweat) + 0.25 (dose) + 
0.64 (x-ray age) 
The third of these orthogonal functions (L3) is a gen- 
Fig. 1. TuqI DNA patterns detected with the DRP probe in six CF 
patients. Lane 1, DR4I5a; lane 2, DR7blw8; lane 3, DR4; lane 4, DR7bl 
w9a; lane 5, DR3a and/or DRw6a; lane 6, DR3aiwSa or DRwGaiwSa. 
The filter was subsequently probed with DQu probe to discriminate 
between specificities DR3 and DRw6 (lanes 5 and 6). 
Of the degree Of Of the three; 
the first and second are functions that contrast sweat 
sodium level with enzyme dose and x-ray age (L3), and 
x-ray age with sweat and enzyme dose values (L2). An- 
gular comparisons of these eigenvectors with those pre- 
viously published [Sing et al., 19821 are given in Table 
VII. Angles near 20 or less indicate a close relationship 
between eigenvectors [Pimentel, 19791. This compari- 
son shows a close relationship between eigenvectors of 
component 3 from this study to component 1 of the pre- 
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TABLE V HLA-DR Vpes in Cluster Groups* 
Cluster group 
HLA 1 + 2  3 + 4  Total 
DNlA 1 0 1 
w10 3 1 4 
w6 9 3 12 
w 8  1 1 2 
1 2 3 5 
2 2 1 3 
3 8 5 13 
4 4 4 8 
5 2 5 7 
7 6 4 10 
8 0 1 1 
* G = 7 570, DF = 10; P = 0 671 
.~ 
1.52% 0.00% 1.52% 
4.55% 1.52% 6.06% 
13.64% 4.55% 18.18% 
1.52% 1.52% 3.03% 
3.03% 4.55% 7.58% 
3.03% 1.52% 4.55% 
12.12% 7.58% 19.70% 
6 06% 6.06% 12.12% 
3.03% 7.58% 10.61% 
9.09% 6.06% 15.15% 
0.00% 1.52% 1.52% 
TABLE VI. HLA-DRw6 Vs. Other V p e s  in Cluster 
Groups* 
Cluster group 
HLA 1 + 2  3 + 4  Total 
Others 29 25 54 
w6 9 3 12 
43.94% 37.88% 81.82% 
13.64% 4.55% 18.18% 
* G = 1.823; DF = 1; P = 0.177. 
TABLE VII. Angular Comparison of Principal Components 
of Old and New Michigan Data 
Old componentsa 
1 2 3 
1 86 135 10* 
Michigan 75 109 84 
Data 15* 128 95 
a Sing et al. [1982]. 
* Indicates close relationship. 
vious study and of component 1 of this study to compo- 
nent 3 of Sing et al. [1982]. When the group of 17 individ- 
uals diagnosed in other medical centers (Chicago) was 
included in this analysis, the orthogonal functions ac- 
counting for variability represented by the three an- 
alyzed variables were as following: L1 = 0.67 (sweat) - 
0.73 (dose) + 0.12 (x-ray age) L2 = -0.42 (sweat) - 
0.25 (dose) + 0.87 (x-ray age) L3 = 0.61 (sweat) + 0.64 
(dose) + 0.47 (x-ray age) 
Functions L1, L2, and L3 account for 36%, 34%, and 
29%, respectively, of the total variability represented by 
the three variables. In angular comparisons of eigenvec- 
tors with the previous results of Sing et al. [1982], only 
component 3 of pooled data shows a close relationship to  
the previous component 1 (Table VIII). 
DISCUSSION 
There have been many reports on genetic hetero- 
geneity in CF. Several studies of allelic association with 
DNA markers have shown that the degree of pancreatic 
involvement (pancreatic sufficiency vs. pancreatic in- 
sufficiency) is genetically determined and is associated 
with different mutant alleles [Devoto et al., 1989; Kerem 
et al., 1989a; Gasparini et al., 19901. It has been shown 
also that American black CF patients, having milder 
lung disease and more severe GI tract complications 
[Stern et al., 19761, have a haplotype distribution that is 
different from Caucasian CF patients [Cutting et al., 
19893. These results are in agreement with the general 
assumption that different clinical symptoms in CF could 
be determined by different mutant CF alleles. Extended 
haplotype data based on DNA markers closely linked to 
the putative disease gene locus [Kerem et al., 1989~1 
shows that the most common haplotype correlates well 
with the AF508,3-bp deletion (present in approximately 
75% of CF cases) and with the occurrence of pancreatic 
insufficiency. The remainder of CF mutant gene pool 
consists of multiple, different haplotypes which may 
each be associated with different mutations, and a 
minor fraction of mutant alleles (approximately 8%) 
may be related to better pancreatic function in a group of 
patients who are pancreatic sufficient. Data have also 
been reported on different allelic frequencies in CF fam- 
ilies with and without meconium ileus [Mornet et al., 
1988, 19891, but they were not confirmed by other au- 
thors [Kerem et al., 1989a, 1989bl. When black and 
Caucasian groups of CF patients were screened sep- 
arately, the presence of particular haplotypes was not 
found to be significantly associated with more severe 
lung disease [Cutting et al., 19891. 
In this study a sample of 59 CF patients was studied. 
Frequencies of haplotypes A, B, C, and D recognized by 
probes XV-2c and KM19 account for 12.7%, 72.9%,3.4%, 
and 11%, respectively, which is in good agreement with 
data reported by others for Caucasian populations 
[Beaudet et al., 1988; Estivill et al., 1987a, 198713; 
Mornet et al., 1988; Vidaud et al., 19891. In our data, the 
B haplotype is not associated with either a more or less 
severe course of the disease measured by the three clini- 
cal variables used. The only statistically significant dif- 
ferences between haplotypes were found in sweat so- 
dium levels a t  the age of diagnosis: individuals with C 
TABLE VIII. Angular Comparison of Principal Components 
for Old and New Combined Data 
Old componentsa 
1 2 3 
1 80 63 140 
Combined 87 114 51 
Data 10* 142 84 
'Sing et al. [19821. 
* Indicates close relationship. 
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and/or D haplotype(s) had a significantly lower sodium 
concentration (Table I) than individuals with haplo- 
type(s) A and/or B. Since most of the patients were B 
haplotype, and most of the B haplotypes studied carried 
the AF508 mutation, this suggests a correlation of 
higher age-corrected sweat electrolyte levels with this 
common mutation. Although not statistically signifi- 
cant, the C haplotype tends to associate with lower pan- 
creatic enzyme dosage corrected for age (Table 111). No 
significant differences were seen in the distribution of 
haplotypes between patients with less and more severe 
lung disease (Table 111, which confirms the data of others 
[Cutting et al., 19891. 
There have been several attempts previously to check 
if the CF mutation segregates with specific HLA anti- 
gen types [Hennequet et al., 1978; Herrod et al., 1979; 
Kaiser et al., 1977; Polymenidis et al., 19731. The gen- 
eral conclusion has been negative as far as  class I HLA 
antigens are concerned. One report showed a statis- 
tically significant association of CF with HLA-B18 [Kai- 
ser et al., 19771. The prevalence of diabetes mellitus in 
patients with CF ranges from 8% to 15% [Knowles et al., 
19881. Clinical characteristics of diabetes in CF patients 
are typical of neither classic type I nor type I1 diabetes 
mellitus. The abnormal insulin secretion in CF patients 
is probably caused by destruction of pancreatic islets 
andior effects of scarification on islet cell secretion or 
paracrine function. Nevertheless, the high incidence of 
diabetes in CF raises a question of the phenomena of 
autoimmunity which are involved in this disease and, 
therefore, the involvement of class I1 HLA antigens in 
CF. We have screened (at the DNA level) part of our 
group of patients with regard to HLA-DR, DQ types. In 
the group of 33 patients, no statistically significant 
prevalence of particular types was shown (Table V). 
However, nearly one fifth of patients screened have the 
HLA-DRw6 allele, which is present in the three most 
common haplotypes characteristic for insulin-depen- 
dent diabetes mellitus (IDDM) [Tuomilehto-Wolf et al., 
19891. The negative results of studies on circulating 
antibodies to islet cells or to insulin [Geffner e t  al., 1988; 
Wilkin et al., 19871 in CF patients point away from a role 
of autoimmune factors in the pathogenesis of diabetes in 
cystic fibrosis. The distribution of all class I1 HLA alleles 
in the cluster groups (Table V) and the distribution of 
HLA-DRw6 vs. all other types in these cluster groups 
(Table VI) has not shown that HLA-DR, DQ types con- 
tribute significantly to phenotypic heterogeneity in CF. 
The lack of statistical significance for these results may 
be due to the small size of the sample studied and the 
marked polymorphism of HLA-DR, DQ antigens. 
A previous study from this laboratory [Sing et al., 
19821 showed that it was possible to group CF patients 
into four significantly different subgroups using a com- 
bination of three clinical variables: degree of pulmonary 
involvement, sweat sodium level, and pancreatic en- 
zyme dosage. We have again found that age-corrected 
variations in the concentration of electrolytes in sweat is 
an important variable for studies of clinical hetero- 
geneity in CF. Indeed, it is the only variable for which 
we have found a significant haplotype association. 
When a currently studied group of patients was divided 
into four clusters using the same set of clinical variables 
and the same statistical procedures and mathematical 
criteria of subgrouping, the distribution of XV-2clKM19 
haplotypes within clusters was random and statistically 
nonsignificant (not shown). It is worth mentioning that 
the current population was smaller than the previous 
one (59 vs. 104 individuals), which may well have af- 
fected the final result of the analysis. Also, individuals 
from this study obviously were not the same as those 
studied previously, although they were from almost 
identical geographic and ethnic backgrounds. On the 
other hand, the principal components which provide a 
general measure of the degree of involvement of the 
three clinical variables in heterogeneity were closely 
related in both studies (Table VIII). When 42 Michigan 
patients were used for analysis, the similarity between 
principal components was much higher (Table VII) than 
when combined data of Michigan and Illinois patients 
were used (Table VIII). This may be due to subjective 
differences in the evaluation of clinical status of patients 
within both groups by their physicians (especially eval- 
uation of chest x-ray scores) or due to real genetic differ- 
ences between these two groups. 
In our study, the XV-2clKM19 B haplotype (strongly 
associated with the AF508 mutation in our material) 
appears to be associated with higher levels of sweat 
electrolytes corrected for age of diagnosis. It is possible 
that this finding is relevant to the presumed hetero- 
zygote advantage of the AF508 mutation; its frequency 
in northern European populations is too great to be 
maintained without a selective advantage. It has been 
argued that heterozygotes for the CF gene may have 
lower intestinal losses of electrolytes during entero- 
pathogen-induced diarrhea [Bijman et al., 19881. Quan- 
titative decreases in heterozygote sweat secretion in 
response to (3-adrenergic stimulation are compatible 
with this hypothesis. Since “summer sickness” (gastro- 
enteritis) of small infants led to high infant mortality 
before fluidielectrolyte therapy was available, a small 
differential in survival due to the presence of absence of 
the AF508 mutation could have led to the high carrier 
frequency. 
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